SY-009

DRUG2 trials

Sponsors

Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Conditions

DiabetesType 2 Diabetes Mellitus

Phase 1

Single Ascending Oral Doses of SY-009 in Healthy Subjects

CompletedNCT04119947

Suzhou Yabao Pharmaceutical R&D Co., Ltd.Diabetes

Start: 2019-03-01End: 2019-05-30Updated: 2019-10-10

Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus

CompletedNCT04345107

Suzhou Yabao Pharmaceutical R&D Co., Ltd.Type 2 Diabetes Mellitus

Start: 2020-05-01End: 2021-09-21Updated: 2022-04-01

Related Papers

Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus

Frontiers in Endocrinology2025-01-281 citations

A randomized double-blind phase Ib clinical trial of SY-009 in patients with type 2 diabetes mellitus

European Journal of Pharmaceutical Sciences2023-11-204 citations